ROSE ROMULUS: Open Payments
NPI 1770909236 · AUSTELL, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$545 in 27 payments from 11 companies in 2025. Trend: 2023 $520 · 2024 $299 · 2025 $545
Food & beverage: $545
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 12 | $232 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $111 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Lilly USA, LLC | 2 | $33 |
| E.R. Squibb & Sons, L.L.C. | 1 | $28 |
| Janssen Pharmaceuticals, Inc | 1 | $21 |
| Exact Sciences Corporation | 1 | $21 |
| ABBVIE INC. | 1 | $20 |
| AstraZeneca Pharmaceuticals LP | 1 | $17 |
| Amgen Inc. | 1 | $15 |
Products named: REXULTI, CAPLYTA, ABILIFY MAINTENA, ABILIFY ASIMTUFII, UZEDY, COBENFY, INVEGA SUSTENNA, Cologuard Collection Kit.
Industry payments across GA — which companies pay providers there.
